The American Society of Clinical Oncology has issued a position statement in the Journal of Clinical Oncology, calling for federal agencies and the cancer research community to broaden clinical trials to include older adults.
The American Society of Clinical Oncology (ASCO) has issued a position statement in the Journal of Clinical Oncology, calling for federal agencies and the cancer research community to broaden clinical trials to include older adults. ASCO also called for redefining eligibility for clinical trials. Despite being a fast-growing segment of the population within the United States, older adults are not well represented in clinical trials (CTs). Additionally, similar to pediatric trials, very few CTs are specifically designed for older adults, and physicians develop their treatment plans by extrapolating results obtained from the healthier, younger population.
The result? Lack of accurate toxicity data and absence of knowledge on age-appropriate trial end points.
With the position statement, ASCO makes 5 recommendations that can improve evidence-generation in the older population:
“Older people living with cancer often have different experiences and outcomes in their treatment than younger cancer patients,” said ASCO President Julie M. Vose, MD, MBA, FASCO. “As we age, for example, the risk of adverse reactions from treatment significantly increases. Older adults must be involved in clinical trials so we can learn the best way to treat older cancer patients resulting in improved outcomes and manageable toxicity.”
Read the press release here: http://bit.ly/1fhRGY4
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen